Apr 11,2022

Survey on the effectiveness of telephone-based communication with relatives of hospitalized cancer patients in COVID-19 era in Italy

No-visitor policies adopted to prevent coronavirus disease-19 (COVID-19) spread in hospital wards have deeply impacted communication with patients and their relatives. Whereas in pre-COVID-19 era family-clinician meetings were held in person, during the pandemic interactions often took place over the phone, frequently causing feelings of uncertainty and distress to the close ones at home. The goal of this study was to assess and improve the effectiveness of structured telephone-based communication with hospitalized onco-hematological patients’ relatives in COVID-19 era.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Apr 12,2022

How technology can improve communication and health outcomes in patients with advanced cancer: an integrative review

Patients facing an advanced cancer diagnosis require clear communication with their clinicians. Technology has been utilized in many different capacities to navigate communication in cancer care, but few authors examine the specific areas of communication from a theoretical perspective. The purpose of this literature review was to (1) identify articles focused on technology-based communication strategies to improve health outcomes in individuals with advanced cancer, and (2) using Epstein and Street’s framework, identify areas in which technology-based communication has been used to improve health outcomes, and (3) identify gaps that exist in technology-based communication care in patients with advanced cancer.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Apr 12,2022

Development and evaluation of the efficacy of a web-based education program among cancer patients undergoing treatment with systemic chemotherapy: a randomized controlled trial

The study aimed to develop a web-based education program among cancer patients undergoing treatment with systemic chemotherapy and to evaluate the efficacy of the program on symptom control, quality of life, self-efficacy, and depression.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Apr 14,2022

GE Healthcare, Elekta collaborate to expand precision radiation therapy access

GE Healthcare (NYSE:GE) and Elekta (EKTA-B.ST) recently announced that they have inked a global commercial collaboration agreement. The partnership covers the radiation oncology field. It’s meant to enable the two companies to provide hospitals a comprehensive offering across imaging and treatment for cancer patients.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Apr 14,2022

Nurse-led telehealth interventions for symptom management in patients with cancer receiving systemic or radiation therapy: a systematic review and meta-analysis

Patients receiving cancer treatments experience many treatment-related symptoms. Telehealth is increasingly being used to support symptom management. The overall aim was to determine the effectiveness of nurse-led telehealth symptom management interventions for patients with cancer receiving systemic or radiation therapy compared to usual care on health service use, quality of life, and symptom severity.

CLINICAL STUDY

#telehealth

View Analyst & Ambassador Comments
Go to original news
Apr 29,2022

Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study

This multicenter (n = 3), retrospective study evaluated all consecutive mRCC patients who participated in the AKO@dom program, which consisted of an app-based and nurse-led weekly patient evaluation at home during the first 3 months of TKI intake. Treatment patterns and modifications were described, and the mean DI (mDI) was calculated at the end of AKO@dom.

CLINICAL STUDY

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Apr 04,2022

Novartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity

Novartis will integrate the Pharmaceuticals and Oncology business units and create two separate commercial organizations with a stronger geographic focus—Innovative Medicines US and Innovative Medicines International. The two units will have full P&L responsibility across all therapeutic areas and ownership of customer experience, marketing and sales, and market access for their respective markets. The elevation and establishment of an independent US commercial organization strengthens Novartis’s ability to achieve its goal of becoming a top-five company in the US in terms of sales while maintaining and growing its leadership position internationally. The new model will also help Novartis bring increased focus and commitment to its core therapeutic areas of Cardiovascular, Hematology, Solid Tumors, Immunology and Neuroscience.

View Analyst & Ambassador Comments
Go to original news
Apr 06,2022

Reimagine Care and University of Colorado Anschutz Medical Campus Collaborate to Provide Home-Centered Care to Bone Marrow Transplant Patients

Reimagine Care today announced that it has collaborated with the University of Colorado Anschutz Medical Campus (CU Anschutz) to deliver care to bone marrow transplant (BMT) patients. The collaboration will leverage specialized clinical technology, advanced remote patient monitoring (RPM), and Reimagine Care’s Virtual Care Center to detect infections earlier and begin life-saving treatments faster to improve outcomes and enhance patient and caregiver experience.

COLLABORATION PARTNERSHIP

#r&d

#rpm

View Analyst & Ambassador Comments
Go to original news
Apr 06,2022

OncoHost enters trial partnership to evaluate resistance to immunotherapy

OncoHost has entered a clinical trial partnership with Roswell Park Comprehensive Cancer Center in the US to evaluate immunotherapy resistance in the PROPHETIC study. The clinical trial site will use OncoHost's precision oncology platform, PROphet®, to conduct proteomic analysis on patients receiving immunotherapy for malignant melanoma, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) to predict their treatment response. The expansion of OncoHost's ongoing clinical trial initiative comes as the company's diagnostic platform shows strong accuracy in host response analysis of late-stage lung cancer patients. So far, OncoHost has launched over 35 trial sites across the globe, extending the reach of the study to new regions and offering a wider body of evidence-based research before the launch of PROphet in the US this year.

COLLABORATION PARTNERSHIP

#r&d

#platform

View Analyst & Ambassador Comments
Go to original news
May 16,2022

OncoHealth™ Unveils Real-World Evidence Dashboard for Pan Tumor, Immunotherapy Research

OncoHealth, the leading digital health company dedicated to oncology, unveiled, today, a new real-world evidence dashboard that enables researchers to study the comparative effectiveness and market performance of immunotherapies. Powered by clinically rich, real-time, pan tumor immunotherapy data and combined with advanced analytics, DashIO™ provides researchers with the ability to query and visualize low-latency real-world data on immune checkpoint inhibitors. OncoHealth will be demonstrating DashIO in booth #522 this week (May 15-18) at the International Society for Pharmacoeconomics and Outcomes (ISPOR) annual meeting being held at the Gaylord National Resort and Convention Center National Harbor in Washington, D.C.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY